Search results for "Graft"

showing 10 items of 907 documents

Tumor Heterogeneity, Single-Cell Sequencing, and Drug Resistance

2016

Tumor heterogeneity has been compared with Darwinian evolution and survival of the fittest. The evolutionary ecosystem of tumors consisting of heterogeneous tumor cell populations represents a considerable challenge to tumor therapy, since all genetically and phenotypically different subpopulations have to be efficiently killed by therapy. Otherwise, even small surviving subpopulations may cause repopulation and refractory tumors. Single-cell sequencing allows for a better understanding of the genomic principles of tumor heterogeneity and represents the basis for more successful tumor treatments. The isolation and sequencing of single tumor cells still represents a considerable technical ch…

0301 basic medicineprecision medicinelcsh:Medicinelcsh:RS1-441Pharmaceutical ScienceReviewsingle-cell sequencingcirculating tumor cellsBiologylaser-capture microdissectionmulti-region sequencingcancer treatmentDNA sequencinglcsh:Pharmacy and materia medicaxenograft tumor models03 medical and health sciencesCirculating tumor cellDrug DiscoveryIllumina dye sequencingMicrodissectionLaser capture microdissectionnext generation sequencingWhole Genome AmplificationGeneticswhole genome amplificationflow cytometrytumor ecosystemslcsh:RRNA sequencing030104 developmental biologySingle cell sequencingintratumoral heterogeneityindividualized therapyMolecular MedicinePyrosequencingmicromanipulationPharmaceuticals
researchProduct

Enzyme replacement therapy with recombinant pro-CTSD (cathepsin D) corrects defective proteolysis and autophagy in neuronal ceroid lipofuscinosis

2019

CTSD (cathepsin D) is one of the major lysosomal proteases indispensable for the maintenance of cellular proteostasis by turning over substrates of endocytosis, phagocytosis and autophagy. Consequently, CTSD deficiency leads to a strong impairment of the lysosomal-autophagy machinery. In mice and humans CTSD dysfunction underlies the congenital variant (CLN10) of neuronal ceroid lipofuscinosis (NCL). NCLs are distinct lysosomal storage disorders (LSDs) sharing various hallmarks, namely accumulation of protein aggregates and ceroid lipofuscin leading to neurodegeneration and blindness. The most established and clinically approved approach to treat LSDs is enzyme replacement therapy (ERT) aim…

0301 basic medicineproteolysisCathepsin DCathepsin DCathepsin BstorageCathepsin L03 medical and health sciencesSequestosome 1Neuronal Ceroid-LipofuscinosesAutophagymedicineAnimalsHumansEnzyme Replacement TherapyeducationMolecular BiologyMice Knockouttherapyeducation.field_of_studyTripeptidyl-Peptidase 1030102 biochemistry & molecular biologybiologyAutophagy; cathepsin D; enzyme replacement therapy; lysosome; neuronal ceroid lipofuscinosis; proteolysis; storage; therapyBrainCell BiologyFibroblastsTripeptidyl peptidase Imedicine.diseaseLRP1Cell biologyDisease Models Animal030104 developmental biologylysosomebiology.proteinAllograft inflammatory factor 1Neuronal ceroid lipofuscinosisneuronal ceroid lipofuscinosisLysosomesResearch PaperAutophagy
researchProduct

The Intention-to-Treat Effect of Bridging Treatments in the Setting of Milan Criteria–In Patients Waiting for Liver Transplantation

2019

In patients with hepatocellular carcinoma (HCC) meeting the Milan criteria (MC), the benefit of locoregional therapies (LRTs) in the context of liver transplantation (LT) is still debated. Initial biases in the selection between treated and untreated patients have yielded conflicting reported results. The study aimed to identify, using a competing risk analysis, risk factors for HCC-dependent LT failure, defined as pretransplant tumor-related delisting or posttransplant recurrence. The study was registered at www.clinicaltrials.gov (identification number NCT03723304). In order to offset the initial limitations of the investigated population, an inverse probability of treatment weighting (IP…

Ablation TechniquesGraft RejectionMaleTime FactorsHepatocellular carcinomaIMPACTmedicine.medical_treatmentSettore MED/18 - CHIRURGIA GENERALEintent to treatLOCOREGIONAL THERAPYKaplan-Meier Estimate030230 surgeryLiver transplantationLIVER TRANSPLANTATION HEPATOCELLULAR CARCINOMA RISK FACTORS OUTCOME PROGNOSTIC SCOREGastroenterologyLiver disease0302 clinical medicineRisk FactorsHEPATOCELLULAR-CARCINOMAHepatocellular carcinoma liver transplantation risk factors intent to treat prognostic score waiting listeducation.field_of_studyLiver NeoplasmsAge FactorsDEATHwaiting listMiddle AgedCANCERprognostic scoreIntention to Treat AnalysisTIMETreatment OutcomeHepatocellular carcinomaDisease ProgressionSURVIVAL030211 gastroenterology & hepatologyFemalemedicine.symptommedicine.medical_specialtyCarcinoma HepatocellularWaiting ListsALPHA-FETOPROTEINPopulationMilan criteriamRECISTRisk AssessmentLesionalpha-fetoprotein03 medical and health sciencesSex FactorsInternal medicinePreoperative CaremedicineHumansHepatology; gastroenterology; hepatocelluar cancer; locoregional therapieseducationRECURRENCEOUTCOMETransplantationLiver transplantationIntention-to-treat analysisHepatologybusiness.industryHEPATOCELLULAR-CARCINOMA; ALPHA-FETOPROTEIN; LOCOREGIONAL THERAPY; RECURRENCE; CANCER; MODEL; TIME; SURVIVAL; IMPACT; DEATHlocoregional therapymedicine.diseaseSettore MED/18Liver TransplantationMODELhepatocellular cancerTumor progressionSurgerybusinessFollow-Up Studies
researchProduct

Single umbilical cord blood with or without CD34+ cells from a third-party donor in adults with leukemia

2017

We retrospectively compared the clinical outcomes of adults with acute leukemia who received single-unit umbilical cord blood (UCB) transplantation (sUCBT) (n = 135) or stem cell transplant using coinfusion of a UCB graft with CD34+ cells from a third-party donor (Haplo-Cord) (n = 72) at different institutions within the Grupo Espanol de Trasplante Hematopoyetico. In multivariable analysis, patients in the Haplo-Cord group showed more rapid neutrophil (hazard ratio [HR], 2.3; 95% confidence interval [CI], 1.5-3.3; P < .001) and platelet recovery (HR, 1.6; 95% CI, 1.2-2.3; P = .015) and lower incidence of chronic graft-versus-host disease (GVHD) (relative risk, 0.5; 95% CI, 0.3-0.8; P = .01)…

Acute leukemiamedicine.medical_specialtyendocrine systemTransplantationbusiness.industryHazard ratioMyeloid leukemiaContext (language use)Hematologymedicine.diseaseUmbilical cordGastroenterologyTransplantation03 medical and health sciencesLeukemia0302 clinical medicinemedicine.anatomical_structureGraft-versus-host disease030220 oncology & carcinogenesisInternal medicineImmunologyMedicinebusiness030215 immunology
researchProduct

Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy

2018

Purpose This multicenter phase II trial evaluated lurbinectedin (PM01183), a selective inhibitor of active transcription of protein-coding genes, in patients with metastatic breast cancer. A unicenter translational substudy assessed potential mechanisms of lurbinectedin resistance. Patients and Methods Two arms were evaluated according to germline BRCA1/2 status: BRCA1/2 mutated (arm A; n = 54) and unselected ( BRCA1/2 wild-type or unknown status; arm B; n = 35). Lurbinectedin starting dose was a 7-mg flat dose and later, 3.5 mg/m2 in arm A. The primary end point was objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST). The translational substudy of resist…

Adult0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyGenes BRCA2Genes BRCA1Phases of clinical researchAntineoplastic AgentsBreast NeoplasmsHeterocyclic Compounds 4 or More RingsMice03 medical and health sciences0302 clinical medicineGermline mutationInternal medicineBiomarkers TumorClinical endpointAnimalsHumansMedicineProgression-free survivalGerm-Line MutationAgedDose-Response Relationship DrugErratabusiness.industryMiddle Agedmedicine.diseaseXenograft Model Antitumor AssaysMetastatic breast cancerProgression-Free SurvivalClinical trial030104 developmental biologyOncologyResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisBiomarker (medicine)FemalebusinessCarbolinesJournal of Clinical Oncology
researchProduct

New insights into the cellular makeup and progenitor potential of palatal connective tissues

2017

The present study investigated the regenerative potential of connective tissues harvested from two palatal areas widely used as donor sites for muco-gingival surgical approaches. Connective tissue grafts (CTGs) were obtained by de-epithelialisation of a free gingival graft (deCTG) and by a split flap approach from a previous donor site (reCTG). Two types of mesenchymal stem cell (MSCs) were isolated and were named de-epithelialised MSCs (deMSCs) and re-entry MSCs (reMSCs). The cells were characterised and cellular functionality was investigated. CTGs were evaluated using immunohistochemical and ultrastructural approaches. No significant differences were observed regarding the frequency of c…

Adult0301 basic medicinePathologymedicine.medical_specialtyHistologyStromal cellCellular differentiationGingivaCD34Connective tissueAntigens CD34BiologyCell LineImmunophenotyping03 medical and health sciences0302 clinical medicineCell MovementOsteogenesismedicineHumansRegenerationProgenitor cellAutograftsInstrumentationConnective Tissue CellsLamina propriaAdipogenesisMucous MembranePalateStem CellsMesenchymal stem cellCell DifferentiationMesenchymal Stem Cells030206 dentistryPlatelet Endothelial Cell Adhesion Molecule-1Medical Laboratory TechnologyHyaluronan Receptors030104 developmental biologymedicine.anatomical_structureConnective TissueFemaleAnatomyStem cellChondrogenesisMicroscopy Research and Technique
researchProduct

Serotherapy with thymoglobulin and alemtuzumab differentially influences frequency and function of natural killer cells after allogeneic stem cell tr…

2007

Although thymoglobulin and alemtuzumab are frequently used in hematopoietic stem cell transplantation (HSCT), little is known of their effects on NK cells, which mediate important functions in post-transplantation immunology. In the present study, we determined NK cell death in vitro using propidium iodide and Annexin V. The NK cell activity in 34 patients at day +30 after allogeneic HSCT was assessed using the CD107a assay. Alemtuzumab and thymoglobulin were similarly very potent in inducing NK cell death in vitro. Even in low concentrations (1 microg/ml) the antibodies induced apoptosis and necrosis in a relevant percentage of NK cells (30%). However, the number of tumor reactive (CD107a+…

AdultAdolescentAntibodies Neoplasmmedicine.medical_treatmentApoptosisHematopoietic stem cell transplantationAntibodies Monoclonal HumanizedLymphocyte DepletionNatural killer cellCell Line TumormedicineHumansTransplantation HomologousProgenitor cellAlemtuzumabAgedAntilymphocyte SerumTransplantationCell DeathThymoglobulinbusiness.industryHematopoietic Stem Cell TransplantationAntibodies MonoclonalHematologyMiddle Agedmedicine.diseaseKiller Cells NaturalTransplantationmedicine.anatomical_structureGraft-versus-host diseaseImmunologyAlemtuzumabStem cellbusinessImmunosuppressive Agentsmedicine.drugBone Marrow Transplantation
researchProduct

Long-term graft function of adult rat and human islets encapsulated in novel alginate-based microcapsules after transplantation in immunocompetent di…

2005

We describe the results of the first study to show that adult rat and human islets can be protected against xenogenic rejection in immunocompetent diabetic mice by encapsulating them in a novel alginate-based microcapsule system with no additional permselective membrane. Nonencapsulated islets lost function within 4–8 days after being transplanted into diabetic Balb/c mice, whereas transplanted encapsulated adult rat or human islets resulted in normoglycemia for &amp;gt;7 months. When rat islet grafts were removed 10 and 36 weeks after transplantation, the mice became immediately hyperglycemic, thus demonstrating the efficacy of the encapsulated islets. The explanted capsules showed only a …

AdultBlood GlucoseMaleendocrine systemmedicine.medical_specialtyTime FactorsRatónAlginatesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentIslets of Langerhans TransplantationCapsulesGraft functionIslets of LangerhansMiceGlucuronic AcidDiabetes mellitusInternal medicineInsulin SecretionInternal MedicineDiabetes MellitusMedicineAnimalsHumansInsulinInsulin secretiongeographyMice Inbred BALB Cgeography.geographical_feature_categorybusiness.industryHexuronic AcidsGraft SurvivalImmunosuppressionDiabetic mousemedicine.diseaseIsletRatsTransplantationEndocrinologybusinessDiabetes
researchProduct

SARS-CoV-2-specific Cell-mediated Immunity in Kidney Transplant Recipients Recovered From COVID-19.

2021

BACKGROUND: The magnitude and kinetics of severe acute respiratory syndrome coronavirus 2-specific cell-mediated immunity (SARS-CoV-2-CMI) in kidney transplant (KT) recipients remain largely unknown. METHODS: We enumerated SARS-CoV-2-specific interferon-I³-producing CD69+ CD4+ and CD8+ T cells at months 4 and 6 from the diagnosis of coronavirus disease 2019 (COVID-19) in 21 KT recipients by intracellular cytokine staining. Overlapping peptides encompassing the SARS-CoV-2 spike (S) glycoprotein N-terminal 1- to 643-amino acid sequence and the membrane protein were used as stimulus. SARS-CoV-2 IgG antibodies targeting the S1 protein were assessed by ELISA at month 6. RESULTS: Detectable (≥0.1…

AdultCD4-Positive T-LymphocytesGraft RejectionMalemedicine.medical_specialty030230 surgeryCD8-Positive T-LymphocytesAntibodies Monoclonal HumanizedGastroenterology03 medical and health sciencesImmunocompromised HostInterferon-gamma0302 clinical medicineCOVID-19 TestingImmunityInternal medicinemedicineHumansInterferon gammaskin and connective tissue diseasesKidney transplantationAgedTransplantationImmunity Cellularbiologybusiness.industrySARS-CoV-2CD69COVID-19Middle Agedmedicine.diseaseKidney TransplantationTacrolimusTransplant RecipientsCOVID-19 Drug TreatmentMonoclonalbiology.protein030211 gastroenterology & hepatologyFemaleAntibodybusinessCD8Immunosuppressive Agentsmedicine.drugFollow-Up StudiesTransplantation
researchProduct

Depletion of naive T cells using clinical grade magnetic CD45RA beads: a new approach for GVHD prophylaxis

2013

Depletion of naive T cells from donor leukapheresis products (LPs) aims at the reduction of alloreactivity, while preserving memory T-cell reactivity (for example, to pathogens). This study established the immunomagnetic depletion procedure under clean room conditions using CD45RA beads and analyzed LPs of six donors for cell composition and functional immune responses. CD45RA depletion resulted in 3.4-4.7 log (median 4.4) reduction of CD45RA(+) T cells, thereby eliminating naive and late effector T cells. B cells were also completely removed, whereas significant proportions of NK cells, monocytes and granulocytes persisted. CD45RA-depleted LPs contained effector and central memory CD4(+) a…

AdultCD4-Positive T-LymphocytesMaleHerpesvirus 4 HumanT-LymphocytesCytomegalovirusGraft vs Host DiseaseEnzyme-Linked Immunosorbent AssayCD8-Positive T-LymphocytesLymphocyte DepletionImmunophenotypingInterferon-gammaInterleukin 21ImmunophenotypingImmune systemAntigenAntigens NeoplasmHumansMedicineLeukapheresisCandidaTransplantationImmunomagnetic Separationbusiness.industryHematologyLeukapheresisFlow Cytometrymedicine.diseaseTransplantationAspergillusGraft-versus-host diseaseImmunologyLeukocyte Common AntigensbusinessCD8Bone Marrow Transplantation
researchProduct